FDA scrutiny of cosmetic drug claims
This article was originally published in The Rose Sheet
Executive Summary
FDA is considering issuing warning letters to cosmetic companies due to "escalating drug claims," the agency says. According to FDA, any company making drug claims for cosmetic products could be subject to regulatory review and action by the agency